Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease ...
Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...
Eight million people in the UK are thought to take the cheap pills, which slow down the production of LDL-cholesterol in the ...
New research suggests that statins, effective cholesterol-lowering drugs, don't cause many of the side effects listed on ...
Research from the University of Oxford found 'incontrovertible evidence' about the cholesterol-busting drug.
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...
Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript February 3, 2026 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.04, expectations were $2.01. Operator: Thank you for ...
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positiv ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results